查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439102

溶瘤病毒治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按病毒类型、按应用、最终用户、地区和竞争细分

Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Virus Type, By Application, by End User, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年全球溶瘤病毒治疗市值为153.8亿美元，预计在预测期内将出现令人印象深刻的增长，到2028年CAGR为23.10%。溶瘤病毒是一类可以感染癌细胞并在癌细胞中选择性复製的病毒，导致它们被破坏或导致它们经历程序性细胞死亡（细胞凋亡）。这些病毒经过工程改造或天然存在，表现出肿瘤选择性偏好，这意味着它们具有先天的能力，能够靶向癌细胞并在癌细胞内复製，同时不伤害正常的健康细胞。溶瘤病毒由于其作为标靶和创新治疗方法的潜力而在癌症治疗领域中获得了关注和重要性。溶瘤病毒对在癌细胞内感染和复製具有固有的偏好。这种选择性通常是基于癌细胞和健康细胞之间的细胞因子和分子特征的差异。一旦进入癌细胞，溶瘤病毒就会复製和繁殖。这种复製最终导致癌细胞裂解（破裂），释放出新形成的病毒颗粒，可以感染邻近的癌细胞。这个过程持续进行，有效地将感染传播到整个肿瘤。

市场概况
预测期 2024-2028
2022 年市场规模 153.8亿美元
2028 年市场规模 530.6亿美元
2023-2028 年CAGR 23.10%
成长最快的细分市场 单纯疱疹病毒 (HSV)
最大的市场 北美洲

正在进行的研究加深了我们对溶瘤病毒的理解，从而开发出更有效、更有针对性的疗法。这种科学进步推动了该领域的创新。溶瘤病毒疗法在治疗各种癌症方面的临床试验和实际应用中取得的积极成果增强了人们对其疗效的信心。展示患者的生存益处和改善的结果一直是关键驱动力。将溶瘤病毒疗法与免疫疗法或标靶疗法等其他治疗方式结合的概念已获得关注。这种组合方法增强了获得更好癌症治疗结果的潜力。医疗保健专业人员、患者和公众对溶瘤病毒疗法的认识和教育的提高有助于其接受和采用。

主要市场驱动因素

研究进展

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型（腺病毒、单纯疱疹病毒（HSV）、麻疹病毒、呼肠孤病毒、牛痘病毒、水疱性口炎病毒（VSV）、其他）
    • 按应用（实体肿瘤、血液恶性肿瘤）
    • 按最终用户（医院、癌症研究机构、生物製药公司）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲溶瘤病毒治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依病毒类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球溶瘤病毒治疗市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • Amgen Inc.
  • Merck & Co., Inc.
  • Oncolytics Biotech Inc
  • PsiOxus Therapeutics Ltd.
  • Vyriad, Inc.
  • Cold Genesys Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Replimune Group Inc.
  • Genelux Corporation

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 20926

Global Oncolytic Virus Therapy Market was valued at USD 15.38 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 23.10% through 2028. Oncolytic viruses are a class of viruses that can infect and selectively replicate in cancer cells, leading to their destruction or causing them to undergo programmed cell death (apoptosis). These viruses are engineered or naturally occurring to exhibit a tumor-selective preference, meaning they have an innate ability to target and replicate within cancerous cells while sparing normal, healthy cells. Oncolytic viruses have gained attention and significance in the field of cancer therapy due to their potential as a targeted and innovative treatment approach. Oncolytic viruses have an inherent preference for infecting and replicating within cancer cells. This selectivity is often based on differences in cellular factors and molecular characteristics between cancer cells and healthy cells. Once inside cancer cells, oncolytic viruses replicate and multiply. This replication eventually leads to the lysis (bursting) of the cancer cell, releasing newly formed viral particles that can infect adjacent cancer cells. This process continues, effectively spreading the infection throughout the tumor.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 15.38 Billion
Market Size 2028USD 53.06 Billion
CAGR 2023-202823.10%
Fastest Growing SegmentHerpes Simplex Virus (HSV)
Largest MarketNorth America

Ongoing research has deepened our understanding of oncolytic viruses, leading to the development of more potent and targeted therapies. This scientific progress drives innovation in the field. Positive outcomes in clinical trials and real-world applications of oncolytic virus therapies for various cancer types have boosted confidence in their efficacy. Demonstrating survival benefits and improved outcomes for patients has been a key driver. The concept of combining oncolytic virus therapy with other treatment modalities, such as immunotherapies or targeted therapies, has gained traction. This combination approach enhances the potential for better cancer treatment outcomes. Increased awareness and education about oncolytic virus therapy among healthcare professionals, patients, and the public have contributed to its acceptance and adoption.

Key Market Drivers

Advancements in Research

Researchers have made significant progress in genetically engineering oncolytic viruses to enhance their tumor-selectivity and therapeutic effectiveness. This includes modifying the virus's ability to replicate in cancer cells while sparing healthy cells. Combining oncolytic virus therapy with other cancer treatments, such as immunotherapies (e.g., immune checkpoint inhibitors) and targeted therapies, has shown promise in improving overall treatment outcomes. Researchers are exploring the best combinations and treatment sequences. Research efforts have led to the development of safer oncolytic viruses with reduced potential for off-target effects. Safety is a critical consideration in regulatory approval and clinical use. The human immune system can neutralize oncolytic viruses. Researchers are developing strategies to evade the host immune response or to enhance the immunostimulatory effects of oncolytic viruses, making them more effective in combating cancer.

Identifying biomarkers that can predict a patient's response to oncolytic virus therapy is a key area of research. This enables a more personalized approach to treatment and ensures that therapy is administered to those who are most likely to benefit. Research has led to innovations in the delivery of oncolytic viruses to tumor sites. This includes the use of nanoparticles, viral vectors, and specialized delivery vehicles to enhance the efficiency of virus delivery. While the Herpes Simplex Virus (HSV) has been prominent, research has expanded to include other virus platforms, such as adenoviruses, reoviruses, and poxviruses. Exploring a variety of virus platforms broadens the scope of oncolytic virus therapy. Ongoing clinical trials have explored the use of oncolytic virus therapy in various cancer types and at different stages of disease. These trials provide valuable data on safety and efficacy, helping to refine treatment protocols.

Researchers are developing methods to stratify patients based on their molecular and genetic profiles, enabling the tailoring of oncolytic virus therapy to individual patients. This personalized approach is considered a significant advancement. Some tumors develop resistance to oncolytic virus therapy over time. Research is ongoing to understand the underlying resistance mechanisms and to develop strategies to overcome them. Advances in the large-scale production and manufacturing of oncolytic viruses have made these therapies more accessible for clinical use. Research is uncovering new applications for oncolytic virus therapy, such as its use in combination with surgery or radiation therapy, as well as its potential in the treatment of rare cancers. This factor will help in the development of the Global Oncolytic Virus Therapy Market.

Increasing Awareness and Education

As patients become more informed about oncolytic virus therapy, they can actively engage in discussions with their healthcare providers and explore treatment options that best suit their needs. This empowerment can lead to increased demand for oncolytic virus therapy. Education and awareness efforts target healthcare professionals, ensuring that they are well-informed about oncolytic virus therapy. When doctors are aware of and understand the therapy, they are more likely to recommend it to eligible patients, thereby driving demand. Increased awareness of oncolytic virus therapy often leads to more patients participating in clinical trials. This not only advances research but also allows patients early access to promising therapies, driving demand in the experimental and post-approval stages. Patient advocacy organizations and support groups for cancer patients often play a role in raising awareness about oncolytic virus therapy. They may advocate for increased research funding, access to therapies, and education for patients and caregivers.

Media coverage, including news stories, documentaries, and social media discussions, can help spread the word about oncolytic virus therapy and its potential benefits. This increased visibility can generate interest and demand. Pharmaceutical companies, healthcare institutions, and nonprofit organizations often conduct educational campaigns to inform the public about oncolytic virus therapy. These campaigns aim to dispel myths, clarify the benefits, and promote the therapy's availability. Medical conferences and workshops are platforms for researchers, clinicians, and industry experts to share the latest developments in oncolytic virus therapy. This knowledge transfer helps disseminate information and promotes its adoption. Education can lead to advocacy for supportive healthcare policies, including reimbursement and coverage by health insurance providers. When oncolytic virus therapy is financially accessible to patients, demand is likely to increase.

Educational initiatives often extend to local communities, raising awareness about cancer treatment options. Community outreach programs may encourage patients to discuss oncolytic virus therapy with their healthcare providers. Awareness campaigns and education can help spread the knowledge of oncolytic virus therapy globally, potentially increasing demand in regions where it is less widely known or accessible. Public awareness can lead to increased research funding, which, in turn, supports the development of new and improved oncolytic virus therapies. More treatment options can drive demand. Hearing success stories and testimonials from patients who have benefited from oncolytic virus therapy can be powerful motivators for others to consider this treatment option. This factor will pace up the demand of the Global Oncolytic Virus Therapy Market.

Diverse Applications

Oncolytic virus therapy is not limited to specific cancer types. It can be applied to a wide range of malignancies, including solid tumors (e.g., melanoma, lung, breast, and colorectal cancers) and hematological cancers (e.g., leukemia and lymphoma). This broad spectrum of applications means that more patients can potentially benefit from oncolytic virus therapy. Oncolytic virus therapy can be used in combination with other treatment modalities, such as chemotherapy, radiation therapy, immunotherapies (e.g., immune checkpoint inhibitors), and targeted therapies. The synergy achieved through combination therapies can enhance treatment outcomes, and this versatility drives demand. Oncolytic virus therapy is not restricted to a particular stage of cancer. It can be used in early-stage cancers as part of curative treatment or in late-stage and recurrent cancers to improve palliative care and extend survival. This flexibility increases the therapy's appeal to both patients and healthcare providers. Some oncolytic virus therapies have shown promise in treating rare and less common cancers. For patients with these conditions, oncolytic virus therapy can represent a novel and potentially more effective treatment option. Oncolytic virus therapy can be applied to localized tumors as well as to tumors that have metastasized to other parts of the body. This dual capability makes it suitable for a wide range of clinical scenarios.

In some cases, oncolytic virus therapy can be administered before or after surgery, acting as neoadjuvant or adjuvant therapy to improve the outcome of surgical interventions. This versatility contributes to its demand. For patients with advanced cancer who may not have curative treatment options, oncolytic virus therapy can be used in palliative care to improve quality of life and extend survival. Diverse applications encourage research and clinical trials in various cancer settings. Ongoing studies and expanded applications provide data that supports the therapy's effectiveness and drive demand. Researchers are exploring the use of oncolytic virus therapy to target specific cancer subtypes with unique characteristics. This precision approach is appealing for patients with such subtypes. The ability to tailor oncolytic virus therapy to individual patients based on their genetic and molecular profiles aligns with the trend of personalized medicine, increasing its demand. This factor will accelerate the demand of the Global Oncolytic Virus Therapy Market.

Key Market Challenges

Efficacy and Safety Concerns

Efficacy can vary among different patients and cancer types. Not all patients respond equally to oncolytic virus therapy, and identifying predictors of response is an ongoing challenge. Tumors are biologically diverse, and this heterogeneity can affect the ability of oncolytic viruses to target and destroy cancer cells effectively. Adapting therapies to address tumor heterogeneity remains a challenge. The tumor microenvironment can be immunosuppressive, hindering the immune system's response to oncolytic viruses. Strategies to overcome immunosuppression are under investigation. Ensuring that oncolytic viruses specifically target cancer cells while sparing healthy tissue is a safety concern. Reducing off-target effects and minimizing collateral damage is a research priority. Tumors can develop resistance to oncolytic virus therapy over time, limiting its long-term effectiveness. Understanding and mitigating resistance mechanisms is a complex challenge. Safety concerns arise from the potential for oncolytic viruses to cause adverse events. Balancing the need for a potent antitumor effect with acceptable safety profiles is a delicate balance.

Manufacturing Complexity

Oncolytic viruses are biologically complex agents that require specialized conditions for growth, propagation, and purification. Their large size, genetic diversity, and replication requirements add to the intricacy of manufacturing. The manufacturing process must adhere to strict sterility standards to prevent contamination, as oncolytic viruses are highly sensitive to contaminants that could compromise their safety and efficacy. Ensuring that each batch of oncolytic viruses is consistent in terms of quality, potency, and safety is essential. Variability in production can lead to unpredictable treatment outcomes. Transitioning from small-scale laboratory production to large-scale manufacturing for clinical or commercial use is challenging. Scaling up the process while maintaining product quality and safety is complex. Specialized equipment and facilities are required to produce oncolytic viruses. These facilities must meet stringent regulatory and quality standards, which can be costly to establish and maintain. Purifying oncolytic viruses from the culture medium can be challenging due to their size and biological properties. Developing efficient purification methods that yield high-quality products is a manufacturing hurdle.

Key Market Trends

Diverse Virus Platforms

Different virus platforms have unique mechanisms of tumor selectivity, replication kinetics, and host interactions. Researchers are studying these properties to optimize each platform for specific cancer types and patient populations. Combining different virus platforms with one another or with other cancer treatments, such as immunotherapies or targeted therapies, is a growing trend. These combinations offer the potential for enhanced therapeutic effects and expanded applications. The diversity of virus platforms allows for a more personalized approach to treatment. By selecting the most suitable virus platform based on a patient's cancer characteristics, oncolytic virus therapy can be tailored to individual needs. The use of diverse virus platforms can help overcome challenges related to resistance mechanisms that tumors may develop against a particular virus. By switching to a different virus platform, clinicians can potentially re-sensitize the tumor to therapy. Different virus platforms come with varying safety profiles. Researchers aim to identify platforms that minimize off-target effects and adverse events while maximizing antitumor effects. The choice of virus platform can influence the method of delivery, such as intratumoral injection, intravenous administration, or targeted delivery systems. These strategies are designed to enhance virus distribution and tumor penetration.

Segmental Insights

Virus Type Insights

In 2022, the Global Oncolytic Virus Therapy Market largest share was held by Herpes Simplex Virus (HSV) segment and is predicted to continue expanding over the coming years. Herpes Simplex Virus (HSV) has been extensively studied and engineered for oncolytic purposes. It has demonstrated efficacy in targeting and destroying cancer cells. The robust body of research supporting HSV-based therapies may have contributed to its dominance. HSV-based oncolytic therapies were among the earliest to enter clinical trials and gain regulatory approval. Their history and experience in the field provide a foundation for their prominence. HSV-based therapies have been developed with a focus on safety, which is crucial for regulatory approval and clinical adoption. This safety profile can make them an attractive choice for patients and healthcare providers. Researchers have made significant advancements in genetically modifying HSV to enhance its tumor-targeting capabilities and reduce its impact on healthy cells. These modifications have improved the therapeutic potential of HSV-based oncolytic viruses.

Application Insights

In 2022, the Global Oncolytic Virus Therapy Market largest share was held by Malignancies segment and is predicted to continue expanding over the coming years. Malignancies, which include various forms of cancer, represent a significant healthcare challenge worldwide. Cancer is a leading cause of morbidity and mortality, and the demand for effective cancer treatments is substantial. The high prevalence of cancer necessitates a diverse range of treatment options, including oncolytic virus therapy. While significant progress has been made in cancer treatment, there are still many types of malignancies, including some advanced or treatment-resistant cancers, that do not respond well to traditional treatments such as chemotherapy, radiation therapy, or targeted therapies. This unmet medical need creates a strong demand for novel and innovative approaches like oncolytic virus therapy. Oncolytic virus therapy has shown promise in targeting a wide spectrum of malignancies, including solid tumors, hematological cancers, and various cancer subtypes. Its potential to treat multiple types of cancer makes it an attractive option for patients and healthcare providers. Ongoing research and clinical trials have demonstrated the effectiveness of oncolytic virus therapy in various malignancies. Positive results from these studies have generated interest and optimism, further driving its adoption.

End-User Insights

In 2022, the Global Oncolytic Virus Therapy Market largest share was held by Biopharmaceutical Companies segment in the forecast period and is predicted to continue expanding over the coming years. Biopharmaceutical companies typically have extensive expertise in research and development, making them well-equipped to advance oncolytic virus therapies from the laboratory to clinical trials and, eventually, to the market. These companies have the resources to conduct the necessary preclinical and clinical research, which is critical for the development of novel therapies. Biopharmaceutical companies often have significant financial resources to invest in the research, development, and commercialization of oncolytic virus therapies. This enables them to fund costly clinical trials, manufacturing processes, and regulatory submissions. Many biopharmaceutical companies form strategic collaborations with academic institutions, research organizations, and other industry players to leverage collective expertise and resources. These partnerships can accelerate the development and market entry of oncolytic virus therapies. Biopharmaceutical companies have a global presence, which allows them to conduct multi-centre clinical trials and seek regulatory approvals in various regions simultaneously. This global reach positions them to capture a significant share of the global market.

Regional Insights

The North America region dominates the Global Oncolytic Virus Therapy Market in 2022. North America, particularly the United States and Canada, has a well-developed and advanced healthcare infrastructure. This includes a robust network of research institutions, hospitals, and biotechnology companies, making it an ideal environment for the development and commercialization of cutting-edge therapies like oncolytic virus therapy. North America is home to many prominent pharmaceutical and biotechnology companies, which invest heavily in research and development. These companies have the resources and expertise to drive innovation in the field of oncolytic virus therapy. The region has a long history of conducting clinical trials for novel medical treatments. This extensive clinical trial infrastructure allows for the testing and evaluation of oncolytic virus therapies, leading to regulatory approvals and market adoption. The U.S. Food and Drug Administration (FDA) and Health Canada have established regulatory frameworks that enable the efficient development and approval of innovative therapies. These agencies have shown openness to oncolytic virus therapies, expediting their evaluation and approval processes.

Key Market Players

Amgen Inc.

Merck & Co., Inc.

Oncolytics Biotech Inc.

PsiOxus Therapeutics Ltd.

Vyriad, Inc.

SillaJen Biotherapeutics

Cold Genesys Inc.

Sorrento Therapeutics, Inc.

Takara Bio Inc.

Replimune Group Inc.

Genelux Corporation

Report Scope:

In this report, the Global Oncolytic Virus Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncolytic Virus Therapy Market, By Virus Type:

  • Adenovirus
  • Herpes Simplex Virus (HSV)
  • Measles Virus
  • Reovirus
  • Vaccinia Virus
  • Vesicular Stomatitis Virus (VSV)
  • Others

Oncolytic Virus Therapy Market, By Application:

  • Solid Tumors
  • Hematological Malignancies

Oncolytic Virus Therapy Market, By End-User:

  • Hospitals
  • Cancer Research Institutes
  • Biopharmaceutical Companies

Oncolytic Virus Therapy Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies presents in the Global Oncolytic Virus Therapy Market.

Available Customizations:

  • Global Oncolytic Virus Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncolytic Virus Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others)
    • 5.2.2. By Application (Solid Tumors, Hematological Malignancies)
    • 5.2.3. By End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Oncolytic Virus Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Virus Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Oncolytic Virus Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Virus Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. India Oncolytic Virus Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Virus Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Oncolytic Virus Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Virus Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Oncolytic Virus Therapy Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Virus Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Oncolytic Virus Therapy Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Virus Type
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By End User

7. Europe Oncolytic Virus Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Virus Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Oncolytic Virus Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Virus Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Oncolytic Virus Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Virus Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Oncolytic Virus Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Virus Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Oncolytic Virus Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Virus Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Oncolytic Virus Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Virus Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. North America Oncolytic Virus Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Virus Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Oncolytic Virus Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Virus Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Oncolytic Virus Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Virus Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Oncolytic Virus Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Virus Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User

9. South America Oncolytic Virus Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Virus Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oncolytic Virus Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Virus Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Oncolytic Virus Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Virus Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Oncolytic Virus Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Virus Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Oncolytic Virus Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Virus Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oncolytic Virus Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Virus Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Oncolytic Virus Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Virus Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Oncolytic Virus Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Virus Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Oncolytic Virus Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Amgen Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Merck & Co., Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Oncolytics Biotech Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. PsiOxus Therapeutics Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Vyriad, Inc.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Cold Genesys Inc.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Sorrento Therapeutics, Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Takara Bio Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Replimune Group Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Genelux Corporation
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer